id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-298886-xidaim04	Leszczyński, Piotr	COVID-19: a short message to rheumatologists	2020-06-29		.txt	text/plain	1571	71	42	In the treatment of cytokine storm in COVID-19, there is a possibility of using a TNF alpha inhibitor (adalimumab) or IL-6 receptor inhibitors (tocilizumab, sarilumab) [6] [7] [8] , which are currently being studied in randomized clinical trials in SARS-CoV-2 infected patients with signs and symptoms of rapidly progressing pneumonia. Our own experience with the combined use of chloroquine and azithromycin or ceftriaxone (n = 34) and tocilizumab (n = 1) in the treatment of severe pneumonia in the course of COVID-19 disease is very good, although it should only be considered as a series of cases (Figs. In accordance with some clinical concerns of rheumatologists, patients with rheumatic diseases treated with disease-modifying drugs (DMARDs) should have a higher risk of SARS-CoV-2 infection. Patient with pharmacologically treated rheumatic disease after close contact (staying at a distance of less than 2 m, for more than 15 minutes, in the last 7 days) with a person with confirmed SARS-CoV-2 infection without clinical symptoms of COVID-19:	./cache/cord-298886-xidaim04.txt	./txt/cord-298886-xidaim04.txt